A phase I study using Bortezomib with weekly idarubicin for the treatment of elderly (> 60 years) and relapsed patients with acute myeloid leukemia (AML)
D Howard, J Liesveld, GL Phillips II, ML Guzman… - Blood, 2008 - Elsevier
In preclinical experiments we have shown that human AML cells overexpress NFkB and
suppression of NFkB by proteasome inhibition directly induces apoptosis in primary AML …
suppression of NFkB by proteasome inhibition directly induces apoptosis in primary AML …
Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus-sensitive B-NHL cells
SH Olejniczak, J Blickwedehl… - Blood, The Journal …, 2010 - ashpublications.org
Resistance to currently available therapies is a major impediment to the successful
treatment of hematological malignancies. Here, we used a model of therapy-resistant B-cell …
treatment of hematological malignancies. Here, we used a model of therapy-resistant B-cell …
[HTML][HTML] Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-κB-mediated cell signals and/or alterations of …
J Park, EK Bae, C Lee, JH Choi, WJ Jung, KS Ahn… - BMB …, 2014 - ncbi.nlm.nih.gov
Bortezomib has been known as the most promising anti-cancer drug for multiple myeloma
(MM). However, recent studies reported that not all MM patients respond to bortezomib. To …
(MM). However, recent studies reported that not all MM patients respond to bortezomib. To …
[PDF][PDF] Point mutation of the proteasome b5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell …
S Lu, J Yang, X Song, S Gong, H Zhou, L Guo… - J Pharmacol Exp …, 2008 - Citeseer
To study the mechanism of acquired resistance to bortezomib, a new antitumor drug that is
the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T …
the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T …
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines
SJ Strauss, K Higginbottom, S Jüliger, L Maharaj… - Cancer research, 2007 - AACR
Bortezomib is a proteasome inhibitor with proven efficacy in multiple myeloma and non–
Hodgkin's lymphoma. This study reports the effects of bortezomib in B-cell lymphoma cell …
Hodgkin's lymphoma. This study reports the effects of bortezomib in B-cell lymphoma cell …
Bortezomib: understanding the mechanism of action
B Piperdi, YH Ling, L Liebes, F Muggia… - Molecular cancer …, 2011 - AACR
This pivotal article by Ling et al. in the August 2002 issue of Molecular Cancer Therapeutics
addressed the mechanism by which a novel proteasome inhibitor, PS341 (bortezomib) …
addressed the mechanism by which a novel proteasome inhibitor, PS341 (bortezomib) …
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer
LHAM de Wilt, G Jansen, YG Assaraf… - Biochemical …, 2012 - Elsevier
The proteasome inhibitor bortezomib, registered for Multiple Myeloma treatment, is currently
explored for activity in solid tumors including non-small cell lung cancer (NSCLC). Here we …
explored for activity in solid tumors including non-small cell lung cancer (NSCLC). Here we …
Phase I trial of bortezomib, mitoxantrone and etoposide in relapsed/refractory acute leukemia
J Filicko-O'Hara, B Mookerjee, MH Carabasi… - Journal of Clinical …, 2008 - ascopubs.org
7071 Background: Bortezomib is a proteasome inhibitor known to effect multiple signaling
pathways. In hematologic malignancies, the inhibition of nuclear factor KB (NF-KB) …
pathways. In hematologic malignancies, the inhibition of nuclear factor KB (NF-KB) …
In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies
K Wiberg, K Carlson, A Åleskog, R Larsson, P Nygren… - Medical oncology, 2009 - Springer
Bortezomib represents a new class of anti-cancer drugs, the proteasome inhibitors. We
evaluated the in vitro activity of bortezomib with regard to tumour-type specificity and …
evaluated the in vitro activity of bortezomib with regard to tumour-type specificity and …
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells
Bortezomib is a highly selective inhibitor of the 26S proteasome and has been approved for
clinical use in the treatment of relapsing and refractory multiple myeloma and mantle cell …
clinical use in the treatment of relapsing and refractory multiple myeloma and mantle cell …